Weight Loss News

Sanofi's Acomplia Flattened By Indian Generics

29 May 2007

Sanofi-Aventis's acomplia (Rimonabant), which is still waiting for the FDA's approval to be sold in the United States, is dealing with stiff competition engendered by its generic versions in India. In Indian drug market, the two companies have started pulling up customers with low-priced versions costing as little as 14 U.S. cents a pill.

India-based pharmaceutical companies namely Cadila Healthcare Ltd. and Torrent Pharmaceuticals Ltd have initiated the promotion of the drug's generic versions with the names Slimona and Rimoslim respectively.

"Torrent is anticipating the sales of 100 million rupees ($2.5 million) in the very first year", said Torrent Pharmaceuticals's spokesman Susim Mohanty

Paris-based Sanofi, who received the FDA approval for sale in Europe last year, is still standing in the row to get green signal from U.S. regulators for the drug, and is in stiff competition with Abbott Laboratories' Meridia and Roche Holding AG's Xenical in addition.

The France's largest drug maker still does not have approval to sell the drug in Indian market despite having submitted an application to the drug authorities last summer.

"It is quite early to enlighten what kind of policy we will employ for the launch of Acomplia in India,'' said Jean Marc Podvin, Sanofi's spokesman. "We have filed an application for registration but it is still not approved"

Cadila started selling its generic version on 5.50 rupees and where as Torrent's pill is available on 8 rupees.

box ticket

female hair loss treatment

real estate licensing

education in real estate investing

real estate licensedes

chiropractic websites

baby toys

Cosmetic Dentistry Beverly Hills -Zadeh Dentistry, a reputable Beverly Hills cosmetic dentistry practice that was voted "L.A.'s Best Dentist" in 2008.

Cosmetic Surgery SEO -Crest Media Medical provides customized medically related websites for cosmetic surgeons, dental and elective medical practices.